HBI-0201-ESO TCRT

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameHBI-0201-ESO TCRT
Drug Alias NameHBI 0201-ESO TCRTHBI-0201-ESO TCRT
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionAnti-NY-ESO-1
TargetsCancer/testis antigen 1
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHadassah Medical Organization
China Registration ClassN/A

Develop Information

Active CompaniesHadassah Medical Organization
Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A